In head and neck squamous cell carcinoma, induction of MMP-1 by CAFs protected cells from cetuximab (epidermal growth factor receptor (EGFR)-targeting monoclonal antibody) [101]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.